Clinical trial
Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular…
NCT00261378 · Boston Scientific Corporation, Industry · Completed
Key facts
| NCT number | NCT00261378 |
|---|---|
| Title | Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation |
| Official title | Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (PRECISION V) |
| Acronym | PRECISIONV |
| Lead sponsor | Boston Scientific Corporation, Industry |
| Collaborators | Biocompatibles UK Ltd Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Liver Cancer |
| Intervention type | Device |
| Interventions | Transarterialchemoembolisation (TACE), DC Bead with Doxorubicin |
| Enrollment | 212 |
| Start date | Nov 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Dec 5, 2005 |
| Last update posted | Jul 21, 2021 |
| Countries | Austria, France, Germany, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: